

**Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue
AR42 in models of spinal muscular atrophy**

Casey J. Lumpkin^{1,2,#}, Ashlee W. Harris^{1,#}, Andrew J. Connell^{1,#}, Ryan W. Kirk¹, Joshua A. Whiting¹, Luciano Saieva³, Livio Pellizzoni^{3,4,5}, Arthur H. M. Burghes^{6,7} and Matthew E. R. Butchbach^{1,2,6,8*}

Supplementary Information

Supplementary Movie. Phenotype of SMN Δ 7 SMA mice treated with AR42 at PND14.

Spontaneous locomotor activity of SMN Δ 7 SMA mice at PND14 that were treated with AR42 (5 mg/kg/day) or vehicle beginning at PND04. Age-matched, non-SMA littermates were also tested to serve as a healthy control.

Supplementary Data: Full-length Blot Images for Immunoblot Figures

Figure 3E




Figure 8B




Figure 9B










Figure 10A



<p>Probe: total AKT</p>		
<p>Probe: P-GSK3β (S9)</p>		
<p>Probe: total GSK3</p>		
<p>Probe: GAPDH</p>	